PDC line Pharma

What we do: PDC*line Pharma is a clinical-stage biotechnology company specializing in the development of innovative cancer vaccines. Utilizing a proprietary plasmacytoid dendritic cell line, the company creates potent, off-the-shelf immunotherapy solutions designed to precisely target tumors. Their main focus is on active immunotherapies for cancers such as non-small cell lung cancer (NSCLC) and colorectal cancer, aiming to stimulate the immune system to attack cancer cells effectively. The company operates within the pharmaceutical and biotech industries, serving healthcare providers, research institutions, and pharmaceutical partners.

Where we are located: The company is headquartered in Liège, Belgium, at Boulevard Patience et Beaujonc 3/6, 4000 Liège. It also maintains offices in France (Grenoble) and South Korea (Seoul), reflecting its international presence.

Short history: Founded in 2014 as a spin-off from the French Blood Bank (Établissement Français du Sang, EFS), PDC*line Pharma has rapidly advanced its proprietary technology. Key milestones include promising Phase I/II clinical trial results in lung cancer (PDC*lung) reported in 2024 and preparations for further Phase II and Phase Ib trials. The company has successfully raised over €61 million in funding and secured a €108 million licensing agreement with LG Chem Life Science in South Korea.

Organization & culture: PDC*line Pharma employs around 42 professionals who work in a collaborative, integrity-driven, and excellence-focused environment. The company fosters a dynamic culture where scientific rigor and creativity are encouraged, enabling the team to push the boundaries of biotechnology and clinical development.

Recent developments: In 2024, PDC*line Pharma reported promising Phase I/II results for its PDC*lung01 vaccine targeting non-small cell lung cancer. The company is advancing clinical trials with plans for randomized Phase II studies and Phase Ib trials involving neoantigen-based vaccines. Additionally, the strategic licensing deal with LG Chem Life Science supports its expansion in Asia and commercialization efforts.